NCT02686476View on ClinicalTrials.gov

Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes

NACompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

September 30, 2017

Study Completion Date

December 31, 2017

Conditions
Non Alcoholic Fatty Liver Disease
Interventions
DRUG

Empagliflozin

group I (n = 50): T2DM patients receiving standard care for T2DM (metformin, sulfonylurea, DPP-4 inhibitor or insulin, in any combination) plus 10 mg of Empagliflozin per day

Trial Locations (1)

122001

Division Of Endocrinology , Medanta The Medicity Sec 38, Gurgaon

All Listed Sponsors
lead

Medanta, The Medicity, India

OTHER

NCT02686476 - Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter